- Home
- CCAP vs DNTH Comparison
CCAP vs DNTH Comparison
Compare CCAP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCAP
- DNTH
- Stock Information
- Founded
- CCAP 2015
- DNTH 2015
- Country
- CCAP United States
- DNTH United States
- Employees
- CCAP N/A
- DNTH N/A
- Industry
- CCAP Finance: Consumer Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CCAP Finance
- DNTH Health Care
- Exchange
- CCAP Nasdaq
- DNTH Nasdaq
- Market Cap
- CCAP 732.0M
- DNTH 711.2M
- IPO Year
- CCAP N/A
- DNTH N/A
- Fundamental
- Price
- CCAP $19.60
- DNTH $21.66
- Analyst Decision
- CCAP Buy
- DNTH Strong Buy
- Analyst Count
- CCAP 6
- DNTH 9
- Target Price
- CCAP $19.17
- DNTH $46.43
- AVG Volume (30 Days)
- CCAP 95.7K
- DNTH 285.9K
- Earning Date
- CCAP 02-19-2025
- DNTH 11-07-2024
- Dividend Yield
- CCAP 10.37%
- DNTH N/A
- EPS Growth
- CCAP 57.74
- DNTH N/A
- EPS
- CCAP 2.55
- DNTH N/A
- Revenue
- CCAP $200,903,000.00
- DNTH $5,366,000.00
- Revenue This Year
- CCAP $9.80
- DNTH $100.14
- Revenue Next Year
- CCAP N/A
- DNTH N/A
- P/E Ratio
- CCAP $7.69
- DNTH N/A
- Revenue Growth
- CCAP 19.05
- DNTH 51.41
- 52 Week Low
- CCAP $15.91
- DNTH $14.82
- 52 Week High
- CCAP $20.03
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- CCAP 58.42
- DNTH 45.12
- Support Level
- CCAP $18.30
- DNTH $18.72
- Resistance Level
- CCAP $19.41
- DNTH $28.65
- Average True Range (ATR)
- CCAP 0.32
- DNTH 2.31
- MACD
- CCAP 0.03
- DNTH -0.33
- Stochastic Oscillator
- CCAP 84.42
- DNTH 32.14
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.